# Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer

> **NCT01199432** · PHASE4 · COMPLETED · sponsor: **Tao OUYANG** · enrollment: 501 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 5-FU（intravenous infusion）+epirubicin+cyclophosphamide
- **DRUG:** 5-FU（intravenous bolus）+epirubicin+cyclophosphamide
- **DRUG:** epirubicin+cyclophosphamide

## Key facts

- **NCT ID:** NCT01199432
- **Lead sponsor:** Tao OUYANG
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 501 (ESTIMATED)
- **Last updated:** 2015-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01199432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01199432, "Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01199432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*